Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Sep 5:13:1276718.
doi: 10.3389/fonc.2023.1276718. eCollection 2023.

Editorial: Prognostic research and precision oncology in upper tract urothelial carcinoma-volume II

Tsung-Mu Yang  1 , Nirmish Singla  2 , Chung-Hsin Chen  3 , Jer-Tsong Hsieh  4 , Hsin-Chih Yeh  5   6   7   8
Affiliations
Editorial

Editorial: Prognostic research and precision oncology in upper tract urothelial carcinoma-volume II

Tsung-Mu Yang et al. Front Oncol. .
No abstract available

Keywords: CCAAT/enhancer-binding protein delta; immunochemotherapy; nomogram; precision oncology; surgical wait time; upper tract urothelial carcinoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Comment on

  • Editorial on the Research Topic Prognostic research and precision oncology in upper tract urothelial carcinoma-volume II

References

    1. Sfakianos JP, Gul Z, Shariat SF, Matin SF, Daneshmand S, Plimack E, et al. . Genetic differences between bladder and upper urinary tract carcinoma: Implications for therapy. Eur Urol Oncol (2021) 4(2):170–9. doi: 10.1016/j.euo.2020.12.007 - DOI - PubMed
    1. Waldert M, Karakiewicz PI, Raman JD, Remzi M, Isbarn H, Lotan Y, et al. . A delay in radical nephroureterectomy can lead to upstaging. BJU Int (2010) 105(6):812–7. doi: 10.1111/j.1464-410X.2009.08821.x - DOI - PubMed
    1. Hankey BF, Ries LA, Edwards BK. The surveillance, epidemiology, and end results program: A national resource. Cancer Epidemiol Biomarkers Prev (1999) 8(12):1117–21. - PubMed
    1. Powles T, Csőszi T, Özgüroğlu M, Matsubara N, Géczi L, Cheng SY, et al. . Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol (2021) 22(7):931–45. doi: 10.1016/s1470-2045(21)00152-2 - DOI - PubMed
    1. Perez Valderrama B, Castellano Gauna D, Pinto Marin A, Mellado Gonzalez B, Puente J, Climent Duran MA, et al. . LBA27 Phase II multicenter, randomized study to evaluate efficacy and safety of avelumab with gemcitabine/carboplatin (CG) vs CG alone in patients with unresectable or metastatic urothelial carcinoma (mUC) who are ineligible to receive cisplatin-based therapy. Ann Oncol (2020) 31:S1158–S9. doi: 10.1016/j.annonc.2020.08.2256 - DOI

Publication types

LinkOut - more resources